Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

95 Downloads (Pure)

Abstract

Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

OriginalsprogEngelsk
TidsskriftClinical Case Reports
Vol/bind5
Udgave nummer12
Sider (fra-til)2085-2087
Antal sider3
ISSN2050-0904
DOI
StatusUdgivet - dec. 2017

Citationsformater